U.S. label record. The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.
A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.↗↗
What the reviewed sources report
The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.↗↗
What remains unresolved?
How do benefits and harms vary in lower-risk populations, after discontinuation, and over follow-up beyond the reviewed trials?↗↗
The cited generic injection label covers long-term weight reduction alongside diet and activity in adults with obesity or overweight with a weight-related condition, and children aged twelve years and older with obesity and body weight above 60 kg. It does not establish the scope of every liraglutide product. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Other warnings address pancreatitis, gallbladder disease, hypoglycemia, increased heart rate, kidney injury from volume depletion, severe gastrointestinal reactions and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 48d493b4dc6af7d7574aedf0a2f7ab6235a9ed62875baffe6c484b5433647541. Extracted XML SHA-256: 26e94f7191fa24c8a25945ac1cd23ef4a95e897a8c9e84520043a4d7ff6edbef.
Reviews summarize selected studies; their scope and limitations are shown above.
European medicine records · 5 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: insulin degludec;liraglutide. EMA record ↗
Marketing authorisation: 2014-09-18. EMA metadata last updated 2024-11-28. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
5625 retrieved · 2 included · 0 excluded · 5623 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Liraglutide"[Title/Abstract] OR "Saxenda"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 5625 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 27295427 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01179048.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 26132939 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01272219.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42737442 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736040 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42732089 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42727920 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42726083 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42725235 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42723821 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42723672 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42718598 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42708757 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42697206 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42695487 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42695140 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42693519 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692655 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692477 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692277 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692107 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42687799 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
14 retrieved · 14 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 14 of 14 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA206321 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA215503 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA BLA208583 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: INSULIN DEGLUDEC, LIRAGLUTIDE.
FDA ANDA217234 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA218115 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA213155 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA215245 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA212552 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA NDA022341 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA217063 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA212972 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA214568 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA215421 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
FDA ANDA217590 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/006620 — include: EMA feed product Ablymico; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006615 — include: EMA feed product Liraglutide STADA; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/001026 — include: EMA feed product Victoza; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/003780 — include: EMA feed product Saxenda; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/002647 — include: EMA feed product Xultophy; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
79 retrieved · 55 included · 0 excluded · 24 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 79 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 5631 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Public assessment report
EMA 8772 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-2647-II-0002 : EPAR - Assessment Report - Variation
EMA 8989 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-PSUSA-00001892-201512 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 10275 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Assessment Report - Variation
EMA 11269 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Medicine overview
EMA 12669 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0005-G : EPAR - Assessment Report - Variation
EMA 13799 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-3780-P46-017 : EPAR - Assessment Report
EMA 19530 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - All Authorised presentations
EMA 21017 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-PSUV-0029 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 21758 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0042 : EPAR - Assessment Report - Variation
EMA 22634 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-PSUSA-00010272-201603 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 29678 — include: Document linked by EMA product number; content unappraised. Xultophy-PSUSA-00010272-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 32913 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Risk-management-plan summary
EMA 34192 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Medicine overview
EMA 35801 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-002647-II-0023 : EPAR - Assessment Report - Variation
EMA 36093 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-P46-0029 : EPAR - Assessment Report
EMA 36517 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Public assessment report
EMA 36966 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - All Authorised presentations
EMA 37786 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-PSUSA-00001892- 201512: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 38842 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-3780-P46-016 : EPAR - Assessment Report
EMA 40021 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0023: EPAR - Assessment Report - Variation
EMA 45716 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0049: EPAR - Assessment Report - Variation
EMA 45717 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Risk-management-plan summary
EMA 45897 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-PSUSA-00001892-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 45901 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-PSUSA-00001892- 201812: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/22/2667 — include: EMA orphan feed identifies liraglutide; designation status: Positive. Orphan designation is not marketing authorization.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
546 retrieved · 0 included · 0 excluded · 546 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Liraglutide" OR "Saxenda" OR "Ablymico" OR "Liraglutide STADA" OR "Victoza" OR "Xultophy"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 546 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT01595789 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01507285 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02292290 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05479591 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01288326 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01800968 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02863419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02140983 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03885297 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01508923 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00700817 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05225974 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01845259 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01602913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01592279 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02777073 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03260881 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03101930 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03555994 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01509742 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02016846 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04034524 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05812183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01934816 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01677104 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Liraglutide?
A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.12
Bottom line from this bounded source set
The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.12
Reviewed study record
SCALE weight-management trial
Design
A double-blind, randomized, placebo-controlled trial assessed body-weight change over 56 weeks alongside lifestyle counseling.1
Population
The trial randomized 3,731 adults without type 2 diabetes who had obesity, or overweight with dyslipidemia or hypertension.1
Outcomes reported
Reported mean weight loss was 8.4 kilograms with liraglutide and 2.8 kilograms with placebo. At least 5% weight loss was reported for 63.2% and 27.1%, respectively, and gastrointestinal events were common.1
Limitations
The sponsor-funded trial combined treatment with lifestyle counseling, excluded type 2 diabetes, and used imputation for the reported mean weight-change analysis.1
Reviewed study record
LEADER cardiovascular-outcomes trial
Design
A double-blind, randomized, placebo-controlled cardiovascular-outcomes trial followed participants for a median of 3.8 years.2
Population
The trial randomized 9,340 adults with type 2 diabetes and high cardiovascular risk in addition to standard care.2
Outcomes reported
The primary composite cardiovascular outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, with a reported hazard ratio of 0.87. Gastrointestinal events were the most common events leading to discontinuation.2
Limitations
The sponsor-funded findings apply to a high-cardiovascular-risk type 2 diabetes population receiving standard care and do not establish the same effect in lower-risk populations.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1411892. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1603827. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Liraglutide?
U.S. label record. The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 29 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
13
FDA Federal Register documents
13
DailyMed SPL versions
2
Canonical profile
Published
Profile structured data
Published
Linked dated records
167
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗